Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tigilanol tiglate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tigilanol tiglate overview
Tigilanol tiglate (EBC-46) is under development for the treatment of refractory cutaneous or subcutaneous tumors of squamous cell carcinoma of head and neck, squamous cell carcinoma of the skin and Merkel cell tumors of the skin, basal cell carcinoma, breast cancer, metastatic colorectal cancer, angiosarcoma, soft tissue sarcoma, leiomyosarcoma, myxofibrosarcoma, myxoinflammatory fibroblastic sarcoma, extraskeletal osteosarcoma, adenocarcinoma, fibrosarcoma, adenoid cystic sarcoma, atypical fibroxanthoma, salivary gland cancer, sino-nasal cancers and laryngeal cancer. It is administered through intratumoral route. The drug candidate is a tiglien-3-one derivative. It acts by targeting protein kinase C (PKC). The drug candidate is developed based on EcoLogic technology.
It was also under development for the treatment of melanoma
QBiotics Group overview
QBiotics Group is a life sciences company that specializes in the discovery and development of novel cell signalling small molecules. The company’s primary activities carries out the application of phenotypic screening for the discovery of first-in-class solutions to challenging medical conditions. Its products include its oncology drug candidate, tigilanol tiglate, and its wound healing drug candidate, EBC-1013. QBiotics Group’s products are primarily used in the medical field for the treatment of conditions such as soft tissue sarcomas, head and neck cancers, and venous leg ulcers. Its products are also being developed for a wide range of chronic and acute wounds and burns. The company operates primarily in the US, the UK, and Australia. QBiotics Group is headquartered in Yungaburra, Queensland, Australia.
For a complete picture of Tigilanol tiglate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
